Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $211K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $211K.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $211K or moves back toward the trailing-twelve-month quarterly average of $52.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$211K— QoQ
Last fiscal yearDec 2025
$572K— YoY
LTMMar 2026
$211K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
572K USD
Year-over-year change
—

Cost of Revenue vs competitors

How UNCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
UNCY Competitors
Cost of Revenue for UNCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$7.28M CAD-18.9%+9.4%39.7%
CBUSCibus, Inc.LTM Mar 2026$1.2M USD-30.9%+56.9%27.9%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$936K USD——23.8%
BMEABiomea Fusion, Inc.LTM Mar 2026$593K USD———
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$211K USD———
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$66K USD-82.3%——
IMUXImmunic, Inc.LTM Mar 2026$33K USD-50.0%——
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 USD———
VXRTVaxart, Inc.LTM Mar 2026$0 USD——0.0%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$228K USD-137.1%——
Peer median (excluding UNCY) —-50.0%+33.1%25.9%

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0951K675K00
Cost of Revenue0000572K
Gross Profit0951K675K0(572K)
Gross Margin—100.0%100.0%——
Research & Development6.08M12.44M12.9M20.01M9.12M
Selling, General & Admin2.9M6.57M8.55M12.1M20.4M
Operating Expenses8.98M19M21.45M32.12M28.95M
Depreciation & Amortization13K161K284K428K572K
EBITDA(9.38M)(17.89M)(30.18M)(36.23M)(25.91M)
EBITDA Margin—-1881.3%-4470.8%——
Operating Income(8.98M)(18.05M)(20.77M)(32.12M)(29.52M)
Operating Margin—-1898.2%-3077.6%——
Interest Income00615K1.26M1.01M
Interest Expense628K6K82K71K71K
Other Income / Expenses(1.04M)(6K)(9.77M)(4.61M)2.96M
Income Before Tax(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Pre-Tax Margin—-1898.8%-4525.0%——
Income Tax Expense00000
Net Income(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Net Margin—-1898.8%-4525.0%——
EPS (Basic)(8.60)(1.20)(1.28)(5.60)(1.67)
EPS (Diluted)(8.60)(1.20)(1.28)(5.60)(1.67)
Weighted Avg Shares1.17M1.51M2.45M6.7M158.87M
Weighted Avg Shares (Diluted)1.17M1.51M2.45M6.7M158.87M

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.